Study Investigates Vision Loss in Patients Using Popular Diabetes and Weight Loss Drugs

Researchers highlight potential links between semaglutide and tirzepatide use and rare eye conditions, urging further investigation and patient vigilance.

A study published in JAMA Ophthalmology examined nine cases of serious eye complications in patients using semaglutide and tirzepatide, drugs commonly prescribed for type 2 diabetes and obesity.
Seven patients were diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION), a condition involving sudden vision loss due to reduced blood flow to the optic nerve.
Researchers hypothesize that rapid blood sugar improvements caused by these medications may contribute to optic nerve damage in some individuals, though causation has not been established.
The study's authors emphasize the need for further research to confirm any potential links and recommend that patients experiencing sudden vision changes seek immediate medical attention.
Semaglutide and tirzepatide are widely used, with nearly 2% of Americans prescribed semaglutide in 2023, underscoring the importance of monitoring potential side effects as usage grows.